NCT00052130Unknown3 期
Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 1,118
- 试验地点
- 80
研究概览
简要总结
This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have Stage III melanoma
- •Must have had all clinically-detectable disease surgically removed
- •Cannot be taking any medications, or undergoing any therapies which compromise the functioning of your immune system (ie. Some corticosteroids, and certain types of radiation therapy)
- •Cannot have HIV or Hepatitis A, B, or C
排除标准
- 未提供
研究者
研究点 (80)
Loading locations...
相似试验
已完成
3 期
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary CirrhosisPBCNCT06715319Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.100
已完成
3 期
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in PanamaCutaneous LeishmaniasisNCT01790659U.S. Army Medical Research and Development Command399
撤回
3 期
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT06735079MGGM LLC146
撤回
3 期
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label ExtensionAlzheimer's DiseaseNCT04187547Cerecin
招募中
3 期
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsMultiple MyelomaNCT06514508Guangzhou Gloria Biosciences Co., Ltd.60